Recent action in the antibody oncology space:
A very significant and recent receipt of breakthrough therapy designation from US Food and Drug Administration for Daratumumab:
http://ir.genmab.com/releasedetail.cfm?ReleaseID=760960
Also, BMS is advertising for roles that would suggest Elotuzumab might be a goer.
http://www.linkedin.com/jobs2/view/12718965?trk=jobs_search_public_seo_page
http://www.linkedin.com/jobs2/view/13523808?trk=jobs_search_public_seo_page
Amgen will want/ need to stay competitive with combination therapy.
Confirmation of a large trial with Amgen would be nice soon.
SM6 production is meant to be done mid year.
good for pab/sm6
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 38 | 43175478 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 10614841 | 12 |
View Market Depth
| Last trade - 16.12pm 01/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable